Abstract:Tumor immunotherapy is the fourth therapy after surgery, chemotherapy, and radiotherapy. It has made great breakthroughs in the treatment of some epithelial tumors and hematological tumors. However, its adverse reactions are common or even more serious, and the response rate in some solid tumors is not satisfactory. With the maturity of genomics and metabolomics technologies, the effect of intestinal microbiota in tumor development and treatment has gradually been recognized. The microbiota may affect tumor immunity by regulating the host immune system and tumor microenvironment. Some bacteria help fight tumors by activating immunity, while some bacteria mediate immunosuppression to help cancer cells escape from the immune system. More and more studies have revealed that the effects and complications of tumor immunotherapy are related to the composition of the gut microbiota. The composition of the intestinal microbiota that is sensitive to treatment or prone to adverse reactions has certain characteristics. These characteristics may be used as biomarkers to predict the prognosis of immunotherapy and may also be developed as “immune potentiators” to assist immunotherapy. Some clinical and preclinical studies have proved that microbial intervention, including microbial transplantation, can improve the sensitivity of immunotherapy or reduce adverse reactions to a certain extent. With the development of gene editing technology and nanotechnology, the design and development of engineered bacteria that contribute to immunotherapy has become a new research hotspot. Based on the relationship between the intestinal microbiota and immunotherapy, the correct mining of microbial information and the development of reasonable and feasible microbial intervention methods are expected to optimize tumor immunotherapy to a large extent and bring new breakthroughs in tumor treatment.

Intestinal microbiota and related metabolites are essential mediators for adoptive γδT cell antitumor immunotherapy

The Microbiota is a Potential Mediator of the Crosstalk Between Γδ T Cells and Tumors

Beneficial Effect of Antibiotics and Microbial Metabolites on Expanded Vδ2Vγ9 T Cells in Hepatocellular Carcinoma Immunotherapy

Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies

The Role of Intestinal Microbiota in Acute Graft-versus-Host Disease

Effect of Gut Microbiota-Derived Metabolites on Immune Checkpoint Inhibitor Therapy: Enemy or Friend?

Gut microbiota-mediated immunomodulation in tumor

Intestinal microbiota: A potential target for enhancing the antitumor efficacy and reducing the toxicity of immune checkpoint inhibitors

The gut microbiome modulate response to immunotherapy in cancer

Targeting gut microbiota for immunotherapy of diseases

The role of the gut microbiota in tumor, immunity, and immunotherapy

Potential mechanisms and targeting strategies of the gut microbiota in antitumor immunity and immunotherapy

Role of gut microbiome in the outcome of cancer immunotherapy

Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect

The Role of Gut Microbiota in Tumor Immunotherapy

A role of gut microbiota metabolites in HLA-E and NKG2 blockage immunotherapy against tumors: new insights for clinical application

Effects of Gut Microbiota on Host Adaptive Immunity Under Immune Homeostasis and Tumor Pathology State

Microbiota: A key factor affecting and regulating the efficacy of immunotherapy

Gut microbiota: impacts on gastrointestinal cancer immunotherapy

Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy

Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome